Home » Topics » BioWorld Science

BioWorld Science
RSS

Lenvatinib demonstrates promising antitumor activity and safety in phase II LEMON study in mCRC

June 19, 2019

Vanflyta approved in Japan for the treatment of relapsed/refractory FLT3-ITD AML

June 19, 2019

Dosing starts in phase I study of gene therapy to treat Danon disease

June 19, 2019

Triumvira Immunologics cleared in U.S and Canada to conduct TAC01-CD19 studies

June 19, 2019

High rates of response seen with repotrectinib in fusion-positive NSCLC

June 19, 2019

FDA accepts IND application for TAK-169

June 19, 2019

Modification improves infliximab safety and response in RA

June 19, 2019

Favipiravir shows efficacy against Bourbon virus

June 19, 2019

Non-oncogene addiction to sirtuin in DLBCL

June 19, 2019

Rozlytrek approved in Japan for NTRK fusion-positive, advanced recurrent solid tumors

June 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...